Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tolebrutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Shares CRL For Sanofi MS Drug Mere Weeks After Rebuff
    FDA Shares CRL For Sanofi MS Drug Mere Weeks After Rebuff

    06 Jan 2026

    // FIERCE PHARMA

    https://www.fiercebiotech.com/biotech/fda-cites-severe-liver-injury-risk-unclear-benefit-behind-sanofis-ms-drug-rejection

    FIERCE PHARMA
    06 Jan 2026
    Share Share
    Tiziana Reports Annual Safety Data For Intranasal Foralumab
    Tiziana Reports Annual Safety Data For Intranasal Foralumab

    29 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/29/3210895/0/en/Tiziana-Files-Annual-Safety-Report-for-Intranasal-Foralumab-with-FDA.html

    GLOBENEWSWIRE
    29 Dec 2025
    Share Share
    Sanofi Provides Update on Tolebrutinib Regulatory Submission
    Sanofi Provides Update on Tolebrutinib Regulatory Submission

    24 Dec 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-12-24-06-00-00-3210238

    PRESS RELEASE
    24 Dec 2025
    Share Share
    Sanofi Updates Tolebrutinib for Primary Progressive MS
    Sanofi Updates Tolebrutinib for Primary Progressive MS

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205094/0/en/Press-Release-Sanofi-provides-update-on-tolebrutinib-in-primary-progressive-multiple-sclerosis.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    Update on the US Regulatory Review of Tolebrutinib in MS
    Update on the US Regulatory Review of Tolebrutinib in MS

    22 Sep 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-09-22-05-00-00-3153624

    PRESS RELEASE
    22 Sep 2025
    Share Share
    Sanofi's Oral Ms Drug FDA Action Date Shifted To December
    Sanofi's Oral Ms Drug FDA Action Date Shifted To December

    22 Sep 2025

    // BIOSPACE

    https://www.biospace.com/fda/fda-action-date-for-sanofis-oral-multiple-sclerosis-drug-bumped-to-december

    BIOSPACE
    22 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.